TWP
SUPN icon

TFO Wealth Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

TFO Wealth Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22
Closed -$1.28K – 915
2022
Q4 		$1.28K Buy
+22
New +$765 ﹤0.01% 315

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TFO Wealth Partners's SUPN Position: Q1 2023 in Review

TFO Wealth Partners sold out of Supernus Pharmaceuticals (SUPN) in Q1 2023, closing a stake of 22 shares — an estimated $1.28K sold.

TFO Wealth Partners first reported a position in SUPN in Q4 2022 and held it in 1 quarter. The position peaked at $1.28K in Q4 2022. 258 funds tracked by Wall St. Rank hold SUPN as of Q1 2023.

  • TFO Wealth Partners reported no remaining Supernus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • TFO Wealth Partners sold 22 Supernus Pharmaceuticals shares in Q1 2023, an estimated $1.28K.
  • TFO Wealth Partners first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • TFO Wealth Partners's Supernus Pharmaceuticals position peaked at $1.28K in Q4 2022.
  • 258 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2023.

Based on TFO Wealth Partners's 13F filing for Q1 2023, filed 3 May 2023.